Kyoichi Okishio

1.6k citations

76 papers · 1.0k indexed · h-index 20

Oncology top 5%
- Lung Cancer Research Studies 32
- Cancer Immunotherapy and Biomarkers 12
- Colorectal Cancer Treatments and Studies 6
- Peptidase Inhibition and Analysis 5
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 45
- Lung Cancer Diagnosis and Treatment 20
Cancer Research
Epidemiology
- Neuroendocrine Tumor Research Advances 7
Molecular Biology
- Cancer therapeutics and mechanisms 6

Co-authors: Shinji Atagi Akihiro Tamiya Tomoya Kawaguchi Tomonori Hirashima Naoki Omachi Motohiro Tamiya Yoshihiko Taniguchi Takayuki Shiroyama
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Oncology (2 papers)Scientific Reports (3 papers)Clinical Cancer Research (1 paper)
Partner nations: Japan United States United Kingdom

In The Last Decade

Kyoichi Okishio

70 papers receiving 995 citations

Peers

Countries citing papers authored by Kyoichi Okishio

Since Specialization

Citations

This map shows the geographic impact of Kyoichi Okishio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyoichi Okishio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyoichi Okishio more than expected).

Fields of papers citing papers by Kyoichi Okishio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyoichi Okishio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyoichi Okishio. The network helps show where Kyoichi Okishio may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kyoichi Okishio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kyoichi Okishio Line = papers co-authored together Kyoichi Okishio links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study Cancer Research Communications ·Kohei Shitara,Motohiro Tamiya,Kyoichi Okishio,Hisashi Hosaka,Katsunori Shinozaki,Nobuhiko Seki,Hiroki Hara,Yukiya Narita,Takeshi Shiraishi,Yosuke Tamura,Akihito Tsuji,Kunihiro Tsuji,Naohiro Watanabe,Hiroshi Tanaka,Toshifumi Yamaguchi,Kensei Yamaguchi,Hiroki Izumi,Yasunori Ushida,Hideaki Suna	2025	0
2	Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies Lung Cancer ·Hiroaki Akamatsu,Tomomi Nishikawa,Yuriko Takeda,Toshihiro Misumi,Tadashi Aoki,Hiroyasu Shoda,Motohiro Yamashita,Noriaki Sakakura,Haruko Daga,Shunichi Sugawara,Kyoichi Okishio,Hirotsugu Kenmotsu,Nobuyuki Yamamoto,Hirohito Tada,Masahiro Tsuboi,Tetsuya Mitsudomi	2025	0
3	Preoperative Maximum Standardized Uptake Value Emphasized in Explainable Machine Learning Model for Predicting the Risk of Recurrence in Resected Non–Small Cell Lung Cancer JCO Clinical Cancer Informatics ·Takafumi Iguchi,Kensuke Kojima,Daiki Hayashi,Toshiteru Tokunaga,Kyoichi Okishio,Hyungeun Yoon	2025	1
4	Nonlinear association between PD-L1 expression levels and the risk of postoperative recurrence in non-small cell lung cancer Scientific Reports ·Kensuke Kojima,Hironobu Samejima,Takafumi Iguchi,Toshiteru Tokunaga,Kyoichi Okishio,Hyungeun Yoon	2024	2
5	Impact of the number of dissected lymph nodes on machine learning-based prediction of postoperative lung cancer recurrence: a single-hospital retrospective cohort study BMJ Open Respiratory Research ·Kensuke Kojima,Hironobu Samejima,Kyoichi Okishio,Toshiteru Tokunaga,Hyungeun Yoon,Shinji Atagi	2024	0
6	Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort Cancer Research Communications ·Makoto Nishio,Shuji Murakami,Hisato Kawakami,Kyoichi Okishio,Motohiro Tamiya,Haruki Kobayashi,Daichi Fujimoto,Shunichi Sugawara,Toshiyuki Kozuki,Yuko Oya,Hiroki Izumi,Takayuki Shiroyama,Miyako Satouchi,Noboru Yamamoto,Shota Kaname,Daiko Matsuoka,Yohei Otake,Takao Takase,Taro Semba,Koichi Azuma	2024	2
7	Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report Thoracic Cancer ·Yoshihiko Taniguchi,Akihiro Tamiya,Atsushi Yanagisawa,Minako Shimaya,Mayu Kawakami,Yuji Inagaki,Nobuhiko Saijo,Yoshinobu Matsuda,Kyoichi Okishio	2023	1
8	A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01 Thoracic Cancer ·Shinji Atagi,Takashi Daimon,Kyoichi Okishio,Kiyoshi Komuta,Yoshio Okano,Koichi Minato,Young Hak Kim,Ryo Usui,Chiharu Tabata,Atsuhisa Tamura,Masaaki Kawahara	2023	1
9	Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial Lung Cancer ·Tsuneo Shimokawa,Hiroaki Okamoto,Ryunosuke Machida,Yuki Misumi,Yukio Hosomi,Yasuto Yoneshima,Hiroshi Tanaka,Kyoichi Okishio,Junichi Simizu,Kōichi Goto,Hiroaki Akamatsu,Kaoru Kubota,Kazuhiko Nakagawa,Hidehito Horinouchi,Masahiko Ando,Tomoko Kataoka,Yuichiro Ohe	2023	4
10	Right‐sided vocal cord paralysis following stereotactic body radiation therapy for non–small‐cell lung cancer: A case report Thoracic Cancer ·Kensuke Kanaoka,Shoich Fukuda,Yuji Inagaki,Yoshihiko Taniguchi,Keiko Nakao,Akihiro Tamiya,Yoshinobu Matsuda,Kyoichi Okishio	2023	2
11	Enhancing tumour content and tumour cell count using microdissection contributes to higher detection rate of genetic mutations by next-generation sequencers Heliyon ·Akihiro Tamiya,Kensuke Kanaoka,Yuji Inagaki,Yoshihiko Taniguchi,Keiko Nakao,Yoshinobu Matsuda,Kyoichi Okishio,Maiko Takeda,Takahiko Kasai,Shigeki Shigeki	2023	1
12	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis Oncology ·Megumu Osaki,Toru Arai,Hiromitsu Sumikawa,Takayuki Takimoto,Naoko Takeuchi,Akihiro Tamiya,Kyoichi Okishio,Yoshikazu Inoue	2023	4
13	First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations JAMA Oncology ·Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe,(unknown)	2023	39
14	A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer Investigational New Drugs ·Akihiro Tamiya,Masahiro Morimoto,Shoichi Fukuda,Yoko Naoki,Tatsuya Ibe,Kyoichi Okishio,Hideto Goto,Akihiro Yoshii,Toshiyuki Kita,Naoyuki Nogami,Yuka Fujita,Shinji Atagi	2018	2
15	The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer Annals of Oncology ·Shoko Sonobe,Yoshihiko Taniguchi,N. Saijo,Yoko Naoki,Akihiro Tamiya,Naoki Omachi,Kyoichi Okishio,Shinji Atagi	2017	6
16	Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer Clinical Lung Cancer ·Masahiro Morimoto,Kyoichi Okishio,Masanori Akira,Naoki Omachi,Akihiro Tamiya,Kazuhiro Asami,Tomoya Kawaguchi,Shinji Atagi	2016	4
17	Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in Japan Thoracic Cancer ·Kazuhiro Asami,Masaaki Kawahara,Tomonori Hirashima,Hidekazu Suzuki,Kyoichi Okishio,Naoki Omachi,Motohiro Tamiya,Akihiro Tamiya,Aya Hirooka,Keiko Nakao,Taisuke Tsuji,Shinji Atagi	2014	2
18	Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer Annals of Oncology ·Akihiro Tamiya,Motohiro Tamiya,Takayuki Shiroyama,Masaki Kanazu,Aya Hirooka,Taisuke Tsuji,Naoko Morishita,Kazuhiro Asami,Hidekazu Suzuki,N. Okamoto,Kyoichi Okishio,Tomoya Kawaguchi,T. Hirashima,Shinji Atagi,Ichiro Kawase	2012	22
19	P2-229: Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small-cell lung cancer Journal of Thoracic Oncology ·Shinji Atagi,Mutsuto Kawahara,Akihito Kubo,Tomoya Kawaguchi,Katsuya Yumine,Kyoichi Okishio,Yoshio Tomizawa,Hikotaro Komatsu,Shimao Fukai	2007	1
20	A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer Lung Cancer ·Shinji Atagi,Masaaki Kawahara,Shigeto Hosoe,Mitsumasa Ogawara,Tomoya Kawaguchi,Kyoichi Okishio,Nobuyuki Naka,Toshihiko Sunami,Shigeki Mitsuoka,Masanori Akira	2002	6

About Kyoichi Okishio

Kyoichi Okishio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 76 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Research Studies (32 papers), Lung Cancer Diagnosis and Treatment (20 papers), Cancer Immunotherapy and Biomarkers (12 papers), Neuroendocrine Tumor Research Advances (7 papers), Cancer therapeutics and mechanisms (6 papers), Colorectal Cancer Treatments and Studies (6 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Oncology (713 citations), Pulmonary and Respiratory Medicine (698 citations) and Cancer Research (79 citations). Kyoichi Okishio has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Shinji Atagi, Akihiro Tamiya, Tomoya Kawaguchi, Tomonori Hirashima, Naoki Omachi, Motohiro Tamiya, Yoshihiko Taniguchi, Takayuki Shiroyama, Kazuhiro Asami and Naoko Takeuchi. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact